Platform Vaccine Applications
Infectious Diseases
DiscoveryResearch
Key Facts
About Chimeron Bio
Chimeron Bio is a private, pre-clinical stage biotech based in Philadelphia, developing a transformative platform for in-vivo genetic medicine. Its core innovation, the ChaESAR™/MultiPlex™ platform, utilizes self-amplifying RNA to deliver large, multi-gene payloads directly to patients, enabling weeks-long expression for complex therapies like CAR-T without ex vivo manufacturing. The company is advancing a pipeline in oncology and autoimmunity, has secured notable NIH grant funding and strategic manufacturing partnerships, and is led by a seasoned team with deep RNA and biotech experience, including a former Moderna CSO on its board.
View full company profileTherapeutic Areas
Other Infectious Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Next-generation mRNA Vaccines | BioNTech | Phase 1 |
| Genetic Molecular Tests | Eurobio Scientific | Commercial |
| LEAPS Technology | CEL-SCI | Pre-clinical |